China
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
The deal could mean that hundreds of licensees in the pool would have access to a broader range of VVC patents
Sponsored
Sponsored
-
Sponsored by Liu, Shen & AssociatesGuanyang Yao of Liu, Shen & Associates reviews several Chinese court rulings on standard-essential patent disputes, including Panasonic v Oppo, and the growing judicial focus on mediation and comparable licences over top-down rate setting -
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations involving active ingredients that are chemically reactive
-
Sponsored by Wanhuida Intellectual PropertyHonghui Hu of Wanhuida Intellectual Property examines how the Supreme People’s Court has clarified the patent scope of drug combination inventions in a patent linkage dispute, offering rare guidance on claim interpretation of pharmaceutical combinations
-
Sponsored by Uni-intel Patent and Trademark Law FirmGump Wang of Uni-intel Patent and Trademark Law Firm explores the strategic value of utility models, which have strong enforcement potential and play a crucial role in China’s patent system
-
Sponsored by AFD China Intellectual Property Law OfficeLinlin Sun and Xia Zheng of AFD China Intellectual Property Law Office cite two key Chinese Supreme People’s Court cases to clarify the conditions under which supplementary experimental data is accepted
-
Sponsored by DEQI Intellectual Property Law CorporationChen Shihua of DEQI Intellectual Property Law Corporation explains China's patent term compensation system, which includes a patent term adjustment for delays and a patent term extension for pharmaceutical patents requiring regulatory approval
